⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11573325 | 0.86 | — | — | |
| SCHEMBL28895561 | 0.78 | PAOX (0.32) | — | |
| SCHEMBL8580369 | 0.77 | — | — | |
| SCHEMBL10518571 | 0.73 | — | — | |
| SCHEMBL6273968 | 0.71 | CYP2C19 (0.52) | — | |
| SCHEMBL3630839 | 0.71 | GAA (0.32) | — | |
| SCHEMBL9056259 | 0.71 | CHRM2 (0.35) | — | |
| SCHEMBL3181489 | 0.70 | — | — | |
| SCHEMBL6600209 | 0.70 | NPC1 (0.40) | — | |
| SCHEMBL17670516 | 0.70 | TSHR (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230404947-A1 | COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-12-21 | — | — | US | disclosed |
| US-20230338310-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-11771665-B2 | Compositions, methods of treatment, and containers including compositions | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210299019-A1 | METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME | CHEMISTRYRX (US) | 2021-09-30 | — | — | US | disclosed |
| US-10905660-B2 | Microparticles | NOVABIOTICS LIMITED (GB) | 2021-02-02 | — | — | US | disclosed |
| EP-3463325-A1 | MICROPARTICLES COMPRISING A SULPHUR-CONTAINING COMPOUND | Novabiotics Limited (GB) | 2019-04-10 | — | — | EP | disclosed |
| WO-2018224813-A1 | USE OF CYSTEAMINE COMPOSITIONS | NOVABIOTICS LIMITED (GB) | 2018-12-13 | — | — | WO | disclosed |
| US-20180344671-A1 | Cysteamine as Neutrophil Elastase Inhibitor | NOVABIOTICS LIMITED (GB) | 2018-12-06 | — | — | US | disclosed |
| US-20180185305-A1 | An Amino Thiol for Use in the Treatment of an Infection Caused by the Bacterium Mycobacterium Spp | NOVABIOTICS LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| EP-3307259-A1 | AN AMINO THIOL FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY THE BACTERIUM MYCOBACTERIUM SPP. | Novabiotics Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2017212249-A1 | MICROPARTICLES COMPRISING A SULPHUR-CONTAINING COMPOUND | NOVABIOTICS LIMITED (GB) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348254-A1 | MICROPARTICLES | NOVABIOTICS LIMITED (GB) | 2017-12-07 | — | — | US | disclosed |
| US-20170348253-A1 | Treatment of Drug-Resistant Microbial Infections | NOVABIOTICS LIMITED (GB) | 2017-12-07 | — | — | US | disclosed |
| EP-3197476-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | Novabiotics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016198842-A1 | AN AMINO THIOL FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY THE BACTERIUM MYCOBACTERIUM SPP. | NOVABIOTICS LIMITED (GB) | 2016-12-15 | — | — | WO | disclosed |
| US-20160102052-A1 | Use of Cysteamine in Treating Infections caused by Yeasts/Moulds | NOVABIOTICS LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| WO-2016046524-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | NOVABIOTICS LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |